NASDAQ
STRO

Sutro Biopharma

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Sutro Biopharma Stock Price

Vitals

Today's Low:
$4.5
Today's High:
$4.675
Open Price:
$4.55
52W Low:
$3.99
52W High:
$8.72
Prev. Close:
$4.6
Volume:
276473

Company Statistics

Market Cap.:
$272.37 million
Book Value:
2.558
Revenue TTM:
$56.87 million
Operating Margin TTM:
-279.34%
Gross Profit TTM:
$-42520000
Profit Margin:
-250.87%
Return on Assets TTM:
-23.35%
Return on Equity TTM:
-78.43%

Company Profile

Sutro Biopharma had its IPO on 2018-09-27 under the ticker symbol STRO.

The company operates in the Healthcare sector and Biotechnology industry. Sutro Biopharma has a staff strength of 297 employees.

Stock update

Shares of Sutro Biopharma opened at $4.55 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.5 - $4.68, and closed at $4.54.

This is a -1.3% slip from the previous day's closing price.

A total volume of 276,473 shares were traded at the close of the day’s session.

In the last one week, shares of Sutro Biopharma have increased by +0.89%.

Sutro Biopharma's Key Ratios

Sutro Biopharma has a market cap of $272.37 million, indicating a price to book ratio of 1.8764 and a price to sales ratio of 6.0527.

In the last 12-months Sutro Biopharma’s revenue was $56.87 million with a gross profit of $-42520000 and an EBITDA of $-152536000. The EBITDA ratio measures Sutro Biopharma's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sutro Biopharma’s operating margin was -279.34% while its return on assets stood at -23.35% with a return of equity of -78.43%.

In Q2, Sutro Biopharma’s quarterly earnings growth was a positive 0% while revenue growth was a negative 62.9%.

Sutro Biopharma’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sutro Biopharma’s profitability.

Sutro Biopharma stock is trading at a EV to sales ratio of 2.2892 and a EV to EBITDA ratio of -1.451. Its price to sales ratio in the trailing 12-months stood at 6.0527.

Sutro Biopharma stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$464.90 million
Total Liabilities
$67.13 million
Operating Cash Flow
$0
Capital Expenditure
$1.60 million
Dividend Payout Ratio
0%

Sutro Biopharma ended 2024 with $464.90 million in total assets and $0 in total liabilities. Its intangible assets were valued at $464.90 million while shareholder equity stood at $154.72 million.

Sutro Biopharma ended 2024 with $0 in deferred long-term liabilities, $67.13 million in other current liabilities, 60000.00 in common stock, $-541189000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $235.10 million and cash and short-term investments were $391.64 million. The company’s total short-term debt was $16,131,000 while long-term debt stood at $0.

Sutro Biopharma’s total current assets stands at $411.99 million while long-term investments were $0 and short-term investments were $156.55 million. Its net receivables were $10.00 million compared to accounts payable of $3.86 million and inventory worth $0.

In 2024, Sutro Biopharma's operating cash flow was $0 while its capital expenditure stood at $1.60 million.

Comparatively, Sutro Biopharma paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.54
52-Week High
$8.72
52-Week Low
$3.99
Analyst Target Price
$18.75

Sutro Biopharma stock is currently trading at $4.54 per share. It touched a 52-week high of $8.72 and a 52-week low of $8.72. Analysts tracking the stock have a 12-month average target price of $18.75.

Its 50-day moving average was $4.54 and 200-day moving average was $5.6 The short ratio stood at 7.33 indicating a short percent outstanding of 0%.

Around 99.5% of the company’s stock are held by insiders while 9414.3% are held by institutions.

Frequently Asked Questions About Sutro Biopharma

The stock symbol (also called stock or share ticker) of Sutro Biopharma is STRO

The IPO of Sutro Biopharma took place on 2018-09-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$17.78
0.29
+1.66%
Asian Paints Limited (ASIANPAINT)
$3256.85
-2.55
-0.08%
$8.39
-0.21
-2.44%
$4.7
0.2
+4.44%
$88
8
+10%
Innoviva Inc (INVA)
$12.44
-0.06
-0.48%
$41.45
0
0%
$109.65
1.16
+1.07%
$0.45
-0.01
-1.74%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company’s product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Address

111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080